Population pharmacokinetic study of cyclosporine based on NONMEM in Chinese liver transplant recipients

Therapeutic Drug Monitoring

Volumn 32, Issue 6, 2010, Pages 715-722

  Sun, Bo ^a   Li, Xiao Yu ^a   Gao, Jun Wei ^a   Rui, Jian Zhong ^b   Guo, Yan Kun ^a   Peng, Zhi Hai ^a   Liu, Gao Lin ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b JINLING HOSPITAL   (China)

Author keywords

cyclosporine (CsA); liver transplantation; nonlinear mixed effects modeling (NONMEM); population pharmacokinetic; therapeutic drug monitoring

Indexed keywords

CYCLOSPORIN A; PREDNISONE;

ADULT; ARTICLE; CHINESE; COMPARTMENT MODEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG MONITORING; FEMALE; GRAFT RECIPIENT; HEMATOCRIT; HUMAN; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NONLINEAR SYSTEM; POPULATION RESEARCH; PRIORITY JOURNAL; SIMULATION; TREATMENT DURATION;

ASIAN CONTINENTAL ANCESTRY GROUP; BAYES THEOREM; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; RETROSPECTIVE STUDIES;

EID: 78649358616     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181fb6ce3     Document Type: Article

References (54)

1. Mueller EA, Kovark JM, Van Bree JB, et al. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res. 1994;11:301-304.
2. Dunn CJ, Wagstaff AJ, Perry CM, et al. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral) in organ transplantation. Drugs. 2001;61:1957-2016.
3. Dumont RJ, Ensom MH. Methods for clinical monitoring of cyclosporin in transplant patients. Clin Pharmacokinet. 2000;38:427-447.
4. Levy G, Thervet E, Lake J, et al. Patient management by Neoral C(2) monitoring: an international consensus statement. Transplantation. 2002; 73:S12-S18.
5. Cole E, Maham N, Cardella C, et al. Clinical benefits of neoral C2 monitoring in the long-term management of renal transplant recipients. Transplantation. 2003;75:2086-2090.
6. Nashan B, Cole E, Levy G, et al. Clinical validation studies of Neoral C(2) monitoring: a review. Transplantation. 2002;73:S3-S11.
7. Wang SM, Lai MK, Chueh SC, et al. Optimal C2 concentration of cyclosporin corrected with good efficacy and safety in Asian kidney transplant recipients. Transplant Proc. 2008;40:2243-2244.
8. Wu KH, Cui YM, Guo JF, et al. Population pharmacokinetics of cyclosporine in clinical renal transplant patients. Drug Metab Dispos. 2005;33:1268-1275.
9. Porta B, Perez-Ruixo JJ, Gorriz JL, et al. Population pharmacokinetics of cyclosporine in kidney transplant patients. Transplant Proc. 1999;31: 2246-2247.
10. Hesselink DA, Gelder TV, Schaik RH, et al. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther. 2004;76:545-556.
11. Parke J, Charles BG. NONMEM population pharmacokinetic modeling of orally administered cyclosporine from routine drug monitoring data after heart transplantation. Ther Drug Monit. 1998;20:284-293.
12. Kyhl LE, Rasmussen SN, Aarons L, et al. Population pharmacokinetics of cyclosporine: influence of covariables and assessment of cyclosporine absorption in kidney, lung, heart and heart + lung transplanted patients. Transplant Proc. 1998;30:1680.
13. Mentre F, Mallet A, Steimer JL, et al. An application of population pharmacokinetics to the clinical use of cyclosporine in bone marrow transplant patients. Transplant Proc. 1988;20:466-470.
14. Tokui K, Kimata T, Uchida K, et al. Dose adjustment strategy for oral microemulsion formulation of cyclosporine: population pharmacokinet-ics-based analysis in kidney transplant patients. Ther Drug Monit. 2004; 26:287-294.
15. Yin OQ, Lau SK, Chow MS. Population pharmacokinetics of cyclosporine in chinese cardiac transplant recipients. Pharmacotherapy. 2006;26:790-797.
16. Rosenbaum SE, Baheti G, Trull AK, et al. Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. Ther Drug Monit. 2005;27:116-122.
17. Dumortier J, Bernard S, Bouffard Y, et al. Conversion from tacrolimus to cyclosporine in liver transplanted patients with diabetes mellitus. Liver Transpl. 2006;12:659-664.
18. Firpi RJ, Zhu H, Morelli G, et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl. 2006;12:51-57.
19. Fouzas I, Daoudaki M, Sotiropoulos GC, et al. Cyclosporine enhances liver regeneration: the role of hepatocyte MHC expression and PGE2 a study releVant to graft immunogenicity. Eur J Med Res. 2008;13:154-162.
20. Charpiat B, Falconi I, Breant V, et al. A population pharmacokinetic model of cyclosporine in the early postoperative phase in patients with liver transplants, and its predictive performance with Bayesian fitting. Ther Drug Monit. 1998;20:158-164.
21. Langers P, Cremers SC, den Hartigh J, et al. Individualized population pharmacokinetic model with limited sampling for cyclosporine monitoring after liver transplantation in clinical practice. Aliment Pharmacol Ther. 2007;26:1447-1454.
22. Wahlby U, Jonsson EN, Karlsson MO. Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn. 2001;28:231-252.
23. Beal SL, Sheiner LB. NONMEM Users Guides; NONMEM Project Group. San Francisco: University of California; 1998.
24. Mandema JW, Verotta D, Sheiner LB. Building population pharmacoki-netic-pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm. 1992;20:511-528.
25. Ette EI. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol. 1997;37:486-495.
26. Ette EI, Ludden TM. Population pharmacokinetic modeling: the importance of informative graphics. Pharm Res. 1995;12:1845-1855.
27. Jadhav PR, Gobburu JV. A new equivalence based metric for predictive check to qualify mixed-effects models. AAPS J. 2005;7:E523-E531.
28. Brendel K, Comets E, Laffont C, et al. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res. 2006;23:2036-2049.
29. Comets E, Brendel K, Mentre F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed. 2008;90: 154-166.
30. Ihaka R, Gentleman R. R: A language for data analysis and graphics. J Comput Graphic. 1996;5:299-314.
31. Parke J, Charles BG. Factors affecting oral cyclosporin disposition after heart transplantation: bootstrap validation of a population pharmacoki-netic model. Eur J Clin Pharmacol. 2000;56:481-487.
32. Saint MF, Marquet P, Jacqz AE, et al. Patient characteristics influencing ciclosporin pharmacokinetics and accurate Bayesian estimation of ciclosporin exposure in heart, lung and kidney transplant patients. Clin Pharmacokinet. 2006;45:905-922.
33. Bourgoin H, Paintaud G, Buchler M, et al. Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients. Br J Clin Pharmacol. 2005;59:18-27.
34. Schadeli F, Marti HP, Frey FJ, et al. Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin micro-emulsion in renal transplant recipients. Clin Pharmacokinet. 2002;41: 59-69.
35. Rousseau A, Monchaud C, Debord J, et al. Bayesian forecasting of oral cyclosporin pharmacokinetics in stable lung transplant recipients with and without cystic fibrosis. Ther Drug Monit. 2003;25:28-35.
36. Monchaud C, Rousseau A, Leger F, et al. Limited sampling strategies using Bayesian estimation or multilinear regression for cyclosporin AUC(0-12) monitoring in cardiac transplant recipients over the first year post-transplantation. Eur J Clin Pharmacol. 2003;58:813-820.
37. Leger F, Debord J, Le Meur Y, et al. Maximum a posteriori Bayesian estimation of oral cyclosporin pharmacokinetics in patients with stable renal transplants. Clin Pharmacokinet. 2002;41:71-80.
38. Debord J, Risco E, Harel M, et al. Application of a gamma model of absorption to oral cyclosporin. Clin Pharmacokinet. 2001;40:375-382.
39. Irtan S, Saint MF, Rousseau A, et al. Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients. Ther Drug Monit. 2007;29:96-102.
40. Rousseau A, Leger F, Le Meur Y, et al. Population pharmacokinetic modeling of oral cyclosporin using NONMEM: comparison of absorption pharmacokinetic models and design of a Bayesian estimator. Ther Drug Monit. 2004;26:23-30.
41. Wade JR, Kelman AW, Howie CA, et al. Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis. J Pharmacokinet Biopharm. 1993;21:209-222.
42. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm. 1983;11:303-319.
43. Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm. 1993;21:735-750.
44. Lalonde RL, Ouellet D, Kimanani EK, et al. Comparison of different methods to evaluate population dose-response and relative potency: importance of interoccasion variability. J Pharmacokinet Biopharm. 1999;27:67-83.
45. Akhlaghi F, Trull AK. Distribution of cyclosporin in organ transplant recipients. Clin Pharmacokinet. 2002;41:615-637.
46. Dusci LJ, Hackett LP, Chiswell GM, et al. Comparison of cyclosporine measurement in whole blood by high performance liquid chromatography, monoclonal fluorescence polarisation immunoassay and monoclonal enzyme multiplied immunoassay. Ther Drug Monit. 1992;14:327-332.
47. Koster RA, Dijkers EC, Uges DR, et al. Robust, high-throughput LC-MS/MS method for therapeutic drug monitoring of cyclosporine, tacrolimus, ever-olimus, and sirolimus in whole blood. Ther Drug Monit. 2009;31:116-125.
48. Morris RG. Cyclosporin assays, metabolite cross-reactivity, and pharma-cokinetic monitoring. Ther Drug Monit. 2000;22:160-162.
49. Aspeslet LJ, Legatt DF, Murphy G, et al. Effect of assay methodology on pharmacokinetic differences between cyclosporine Neoral and Sandim-mune formulations. Clin Chem. 1997;43:104-108.
50. Iwi G, Millard RK, Palmer AM, et al. Bootstrap resampling: a powerful method of assessing confidence intervals for doses from experimental data. Phys Med Biol. 1999;44:N55-N62.
51. Ette EI. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol. 1997;37:486-495.
52. Dai GW, Pfister M, Anne BC, et al. Importance of characterizing determinants of variability in exposure: application to dasatinib in subjects with chronic myeloid leukemia. J Clin Pharmacol. 2008;48:1254-1269.
53. Punyawudho B, Ramsay RE, Macias FM, et al. Population pharmacokinetics of lamotrigine in elderly patients. J Clin Pharmacol. 2008;48:455-463.
54. Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther. 2007;82:17-20.